Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 2 1

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 21Nasopharyngeal Carcinoma 7Colorectal Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Nasopharyngeal Neoplasms 3Lung Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Sarcoma 2Recurrence 2Neoplasms 2Head and Neck Neoplasms 2Unresectable Non-small Cell Lung Cancer 1Squamous Non-small Cell Lung Cancer 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Solid Tumors 1Optic Nerve Glioma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma, T-Cell 1Locally Advanced Squamous Non-small Cell Lung Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Cancer Organoids 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lung Neoplasms × Endostatins × Clear all
NCT04613284 2020-11-03

RELIEF

Shanghai Chest Hospital

Phase 4 Unknown
97 enrolled
Thoracic

Lung Neoplasms

NCT02375022 2015-03-24

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Zhejiang University

Phase 2 Unknown
10 enrolled
Thoracic

Lung Neoplasms

NCT02350361 2015-01-29

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Peking University Third Hospital

Phase 2/3 Unknown
60 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡